Skip to main content

Advertisement

Table 2 Baseline characteristics of included studies in meta-analysis

From: Comparison of survival benefits of nephron-sparing intervention or active surveillance for patients with localized renal masses: a systematic review and meta-analysis

Study detail No. of patients, type Sex, Male/Female Median age (years) Median tumor size (centimeter) Median follow-up duration (months)
Alam R et al 2018 [14] PN 231 145/86 61.3 2.4  
TA 27 13/14 71.8 2.1 36.0 (Total)
AS 339 190/149 70.6 1.8  
AS 1978 NA NA 2.8 > 42.2
Miller BL et al 2018 [15] PN 31 NA Oncocytoma 69.5 chRCC 57.0 NA  
TA 14 NA NA 39.9 (Total)
AS 90 NA NA  
Tang DH et al 2017 [16] PN 31 24/7 81.0 3.2 51.0 (Total)
AS 31 18/13 83.0 2.7
Larcher A et al 2015 [17] TA 553 308/245 77.0 2.7 30.0 (Total)
AS 1307 778/529 78.0 2.8
Patel HD et al 2015 [18] PN 1849 1070/779 65–69 589(31.5%) 70–74 569(27.5%) 75–79 463(25.2%) 80–84 191(19.5%) ≥85 37(8.9%) < 2 cm 454(41.2%) 2- < 3 cm 776(31.8%) 3- ≤ 4 cm 614 (17.0%) 56.0 (Total)
AS 754 399/355 65–69 589(31.5%) 70–74 569(27.5%) 75–79 463(25.2%) 80–84 191(19.5%) ≥85 37(8.9%) < 2 cm 134(12.2%) 2- < 3 cm 258(10.6%) 3- ≤ 4 cm 361(10.0%)
Patel N et al 2012 [19] PN 90 NA 58.9 2.69 33.0
AS 71 52/19 71.9 2.2 34.0
Lane BR et al 2010 [20] NSI 286 200/86 78.0 3.0 46.8 (Total)
AS 105 58/47 81.0 2.3
  1. AS active surveillance, chRCC chromophobe renal cell carcinoma, NA not available, NSI nephron-sparing intervention, PN partial nephrectomy, TA thermal ablation